118 related articles for article (PubMed ID: 24088695)
21. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
Kakinuma H; Oi T; Hashimoto-Tsuchiya Y; Arai M; Kawakita Y; Fukasawa Y; Iida I; Hagima N; Takeuchi H; Chino Y; Asami J; Okumura-Kitajima L; Io F; Yamamoto D; Miyata N; Takahashi T; Uchida S; Yamamoto K
J Med Chem; 2010 Apr; 53(8):3247-61. PubMed ID: 20302302
[TBL] [Abstract][Full Text] [Related]
22. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
23. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
24. Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.
Lee SH; Kim MJ; Lee SH; Kim J; Park HJ; Lee J
Eur J Med Chem; 2011 Jul; 46(7):2662-75. PubMed ID: 21514014
[TBL] [Abstract][Full Text] [Related]
25. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
Wan HX; Shen JK
Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
[TBL] [Abstract][Full Text] [Related]
26. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
27. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
[No Abstract] [Full Text] [Related]
28. Synthesis and Structure-Activity Relationship of C-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors.
Kuroda S; Kobashi Y; Kawamura M; Kawabe K; Shiozawa F; Hamada M; Shimizu Y; Okumura-Kitajima L; Koretsune H; Kimura K; Yamamoto K; Kakinuma H
Chem Pharm Bull (Tokyo); 2020; 68(7):635-652. PubMed ID: 32611999
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC
Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
[TBL] [Abstract][Full Text] [Related]
31. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
Ding Y; Mao L; Xu D; Xie H; Yang L; Xu H; Geng W; Gao Y; Xia C; Zhang X; Meng Q; Wu D; Zhao J; Hu W
Bioorg Med Chem Lett; 2015 Jul; 25(14):2744-8. PubMed ID: 26026363
[TBL] [Abstract][Full Text] [Related]
32. [Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor].
Takasu T; Takakura S; Hamada K
Nihon Yakurigaku Zasshi; 2016; 148(5):266-271. PubMed ID: 27803440
[No Abstract] [Full Text] [Related]
33. Pyrazole-O-glucosides as novel Na(+)-glucose cotransporter (SGLT) inhibitors.
Ohsumi K; Matsueda H; Hatanaka T; Hirama R; Umemura T; Oonuki A; Ishida N; Kageyama Y; Maezono K; Kondo N
Bioorg Med Chem Lett; 2003 Jul; 13(14):2269-72. PubMed ID: 12824015
[TBL] [Abstract][Full Text] [Related]
34. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.
Yuan MC; Yeh TK; Chen CT; Song JS; Huang YC; Hsieh TC; Huang CY; Huang YL; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
Eur J Med Chem; 2018 Jan; 143():611-620. PubMed ID: 29216560
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.
Zhao X; Sun B; Zheng H; Liu J; Qian L; Wang X; Lou H
Bioorg Med Chem Lett; 2018 Jul; 28(12):2201-2205. PubMed ID: 29764742
[TBL] [Abstract][Full Text] [Related]
36. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats.
Bickel M; Brummerhop H; Frick W; Glombik H; Herling AW; Heuer HO; Plettenburg O; Theis S; Werner U; Kramer W
Arzneimittelforschung; 2008; 58(11):574-80. PubMed ID: 19137908
[TBL] [Abstract][Full Text] [Related]
37. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
38. C-Aryl Glucosides with Substituents at the Distal Aryl Ring as Sodium-Dependent Glucose Cotransporter Inhibitors for the Treatment of Diabetes Mellitus.
Wang X; Li Y; Yang B; Li Z; Huang W; Qian H
Chem Biol Drug Des; 2015 Aug; 86(2):246-53. PubMed ID: 25443983
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
[TBL] [Abstract][Full Text] [Related]
40. Design, syntheses, and SAR studies of carbocyclic analogues of sergliflozin as potent sodium-dependent glucose cotransporter 2 inhibitors.
Shing TK; Ng WL; Chan JY; Lau CB
Angew Chem Int Ed Engl; 2013 Aug; 52(32):8401-5. PubMed ID: 23784919
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
